Circulating Vgamma2/Vdelta2 T cells in human and non-human primates respond to small molecular weight non-peptidic phosphoantigens in a major histocompatibility complex (MHC)-unrestricted manner. These responses are encoded by the Vgamma2/Jgamma1.2 chain of the T-cell receptor and are positively selected during early development to create a biased repertoire in adults. We characterized the Vgamma2 chain in cynomolgus macaques (Macaca fascicularis) to develop a non-human primate model for studying the effects of infection and therapy on the circulating Vgamma2/Vdelta2 T-cell subset. The cynomolgus macaque Vgamma2 chain was highly homologous to the Vgamma2 chain from human beings and rhesus macaques (Macaca mulatta), though we noted conserved substitutions in critical residues within the CDR3 for both macaque species. Despite these substitutions, Vgamma2/Vdelta2+ T cells from cynomolgus monkeys exhibited polyclonal responses to two different phosphoantigens. Proliferative responses were observed with both isopentenylpyrophosphate and alendronate, but stronger interferon-gamma secretory responses were observed with isopentenylpyrophosphate. In vitro stimulation and expansion led to selective outgrowth of the Vgamma2/Jgamma1.2 subset, with a marked shift in the Vgamma2 spectratype. As a result of the less biased starting repertoire for Vgamma2, the cynomolgus macaque constitutes a sensitive model for examining the effects of in vitro or in vivo treatments on the Vgamma2/Vdelta2 T-cell population. Our studies establish the value of cynomolgus macaques as a model for Vgamma2/Vdelta2 T-cell responses to non-peptidic antigens, and further evidence the remarkable evolutionary conservation of this unusual, phosphoantigen-responsive T-cell subset that is found only in primate species.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1782144PMC
http://dx.doi.org/10.1111/j.1365-2567.2005.02153.xDOI Listing

Publication Analysis

Top Keywords

vgamma2/vdelta2 t-cell
16
vgamma2 chain
12
macaca fascicularis
8
vgamma2/jgamma12 subset
8
circulating vgamma2/vdelta2
8
cynomolgus macaques
8
macaques macaca
8
t-cell subset
8
cynomolgus macaque
8
responses observed
8

Similar Publications

LncRNA SNHG16 Inhibits Intracellular Growth Involving Cathelicidin Pathway, Autophagy, and Effector Cytokines Production.

ACS Omega

October 2024

Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Biosafety Level 3 Laboratory, Shanghai Institute of Infectious Disease and Biosecurity, Department of Medical Microbiology and Parasitology, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China.

Long noncoding small nucleolar RNA (LncRNA) host gene 16 (SNHG16) is associated with certain diseases, including cancers. However, its role and mechanism in () infection remain unclear. Here, we demonstrated that SNHG16 expression levels were suppressed in peripheral blood mononuclear cells (PBMCs) and CD14 monocytes of tuberculosis (TB) patients.

View Article and Find Full Text PDF

Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug.

Sci Rep

July 2017

Department of Surgery, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.

Article Synopsis
  • Bisphosphonates have been used in treating breast cancer and multiple myeloma, working alongside γδ T cell immunotherapy, but traditional bisphosphonates have limited effectiveness and cause bone-related side effects.* -
  • Researchers developed bisphosphonate prodrugs, which enter cancer cells and convert to active forms that more effectively stimulate γδ T cells to attack tumors compared to standard treatments.* -
  • In preclinical models, a specific prodrug enhanced the effectiveness of γδ T cell therapy, leading to improved survival rates in mice with tumors, suggesting a promising new combination approach for cancer treatment.*
View Article and Find Full Text PDF

Immune biology of Ag-specific γδ T cells in infections.

Cell Mol Life Sci

July 2011

Department of Microbiology and Immunology, Center for Primate Biomedical Research, University of Illinois College of Medicine Chicago, Chicago, IL 60612, USA.

Accumulating evidence suggests that human γδ T cells act as non-classical T cells and contribute to both innate and adaptive immune responses in infections. Vγ2 Vδ2 T (also termed Vγ9 Vδ2 T) cells exist only in primates, and in humans represent a dominant circulating γδ T-cell subset. Primate Vγ2 Vδ2 T cells are the only γδ T cell subset capable of recognizing microbial phosphoantigen.

View Article and Find Full Text PDF

Human Vγ2 Vδ2-bearing T cells have recently received much attention in cancer immunotherapy. In this study, we conducted a phase I/II clinical trial of the adoptive transfer of γδ T cells to patients with advanced renal cell carcinoma. Eleven patients who had undergone nephrectomy and had lung metastasis were enrolled.

View Article and Find Full Text PDF

The efficacy of current cancer vaccines is limited by the functional heterogeneity and poor availability and expansion of professional antigen-presenting cells (APCs). Besides their potent innate effector properties, gammadelta T cells have been suggested to be involved in the initiation and maintenance of adaptive immune responses. Here, we investigated the capacity of human gammadelta T cells to induce expansion of virus-specific T cells to Epstein Barr virus (EBV) antigens.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!